Lack of immune potentiation by complexing HBsAg in a heat-inactivated hepatitis B Vaccine with antibody in hepatitis B immunoglobulin

Authors

  • Dr. P. Nico Lelie,

    Corresponding author
    1. Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam
    2. “Piusoord,” Centre for Service to Mentally Retarded Patients, Tilburg, and Craeyenburch, Nootdorp, The Netherlands
    • Publication Secretariat, Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, P.O. Box 9406, 1006 AK Amsterdam, The Netherlands
    Search for more papers by this author
  • Peter J. A. J. van Amelsfoort,

    1. Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam
    2. “Piusoord,” Centre for Service to Mentally Retarded Patients, Tilburg, and Craeyenburch, Nootdorp, The Netherlands
    Search for more papers by this author
  • C. S. Martine de Groot,

    1. Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam
    2. “Piusoord,” Centre for Service to Mentally Retarded Patients, Tilburg, and Craeyenburch, Nootdorp, The Netherlands
    Search for more papers by this author
  • Ed Bakker,

    1. Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam
    2. “Piusoord,” Centre for Service to Mentally Retarded Patients, Tilburg, and Craeyenburch, Nootdorp, The Netherlands
    Search for more papers by this author
  • Wim Schaasberg,

    1. Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam
    2. “Piusoord,” Centre for Service to Mentally Retarded Patients, Tilburg, and Craeyenburch, Nootdorp, The Netherlands
    Search for more papers by this author
  • Jos C. M. Niessen,

    1. Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam
    2. “Piusoord,” Centre for Service to Mentally Retarded Patients, Tilburg, and Craeyenburch, Nootdorp, The Netherlands
    Search for more papers by this author
  • Henk W. Reesink

    1. Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, University of Amsterdam, Amsterdam
    2. “Piusoord,” Centre for Service to Mentally Retarded Patients, Tilburg, and Craeyenburch, Nootdorp, The Netherlands
    Search for more papers by this author

Abstract

In a randomized, dose-response study among 305 health care workers, we examined whether the immunogenicity of a heat-inactivated hepatitis B vaccine could be enhanced when HBsAg was complexed by anti-HBs contained in hepatitis B immunoglobulin either at equivalent proportions or at 10-fold antigen excess. The dose of HBsAg in the control vaccine as well as in the two complexed vaccine preparations could be reduced from the standard value (3 μg) to 0.6 μg per injection without affecting the antibody response in the vaccinees. Still lower dosages of HBsAg in the three vaccine preparations induced significantly lower but comparable anti-HBs responses. These results indicate that, in man, using a heat-inactivated plasma vaccine, addition of anti-HBs contained in hepatitis B immunoglobulin does not potentiate the immunogenicity of HBsAg.

Ancillary